14:16 , Nov 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Scleroderma Mouse and cell cultures studies suggest agonizing LTBR in adipose-derived mesenchymal stromal cell (ADSC) grafts could help treat skin fibrosis in scleroderma. ADSC numbers were lower in the dermal white adipose tissue (WAT) in...
07:00 , Oct 23, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Chronic lymphocytic leukemia (CLL) Lymphotoxin-a (LTa); lymphotoxin-b receptor (LTBR); chemokine CXC motif ligand 13 (CXCL13); CXC chemokine receptor...
07:00 , Mar 27, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HBV Lymphotoxin-b receptor (LTBR) In vitro studies suggest activating LTBR could help treat HBV infection. HBV...
07:00 , Aug 29, 2011 |  BioCentury  |  Strategy

R&D reboot

Charged with a mandate to reinvigorate and streamline R&D and ensure investors see value for money spent, Biogen Idec Inc.'s new management has pruned the pipeline and instilled a new culture of intelligent risk taking. CEO...
07:00 , May 5, 2011 |  BC Innovations  |  Cover Story

LIGHTs out for asthma

Two years after Kyowa Hakko Kirin Co. Ltd.granted sanofi-aventis Groupan exclusive license to an antibody against the tumor necrosis factor ligand LIGHT to treat irritable bowel disease, researchers at the La Jolla Institute for Allergy...
07:00 , Apr 28, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Asthma Tumor necrosis factor ligand superfamily member 14 (TNFSF14; LIGHT; CD258) Mouse...
07:00 , Apr 8, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Bacterial infection Lymphotoxin-b receptor (LTBR) In vitro and mouse studies suggest that upregulating LTBR signaling in...
07:00 , Mar 25, 2010 |  BC Innovations  |  Cover Story

A B cell burden in prostate cancer

Although castration therapies such as androgen ablation are standard prostate cancer treatments, many patients develop resistance in 12-18 months.1 Now, researchers from the University of California, San Diego and Scripps Florida have found that castration...
07:00 , Mar 25, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Lymphotoxin-b (LTb); LTb receptor (LTBR) A study in mice and in patient samples suggests that...
07:00 , Oct 13, 2008 |  BC Week In Review  |  Clinical News

Baminercept: Phase IIb data

Top-line data from a double-blind, placebo-controlled, international Phase IIb trial (104RA202) in 380 RA patients who had inadequate response to conventional DMARD therapy, showed that all 5 doses of baminercept missed the primary and secondary...